Market Overview

The Drug Discovery Services market industry is projected to exhibit a significant CAGR of 13.92% during the forecast period. Developing Re-appropriating of Drug Advancement and Expanding Exploration and Improvement Expenses are the key market drivers upgrading the Drug Discovery Services market development.
Drug and biopharmaceutical organizations are picking completely coordinated or practical rethinking services for drug innovative work from the early improvement stage to the late-stage advancement stage due to expanded Research and development consumptions. While drug organizations are under extraordinary strain to monitor fixed costs, re-appropriating has arisen as a strategic answer for the absence of inside assets required for new item improvement. Enormous pharma firms are changing to a more streamlined corporate methodology that unequivocally stresses rethinking.
Expanding need for imaginative therapeutics across a scope of restorative objectives. Drug-finding services Rising requirement for imaginative therapies for constant sicknesses and headways in the medical care industry are anticipated to be the primary drivers of market development. Drug and biopharmaceutical organizations actually contract their innovative work (Research and Development) activities to CROs, who offer Research and development services and make commitment models to boost Research and development productivity. Legislatures and drug enterprises are compelled to search for answers and lift their interest in clinical preliminaries because of the expanded weight of persistent sicknesses. Subsequently, there will be a more prominent requirement for drug discovery services.

Market Segmentation

Based on Drug Type, the Drug Discovery Services market has been classified into Small Molecule Drugs, Biologics’ Based on type, the market is divided into Drug metabolism and pharmacokinetics (DMPK) Services, Pharmaceutical Services, and Others. Therapeutic Areas of the Drug Discovery Services market are bifurcated into data into Oncology, Others.

Regional Analysis

North America is likely to drive the global Drug Discovery Services market due to the higher interest in drug discovery Research and development, critical firms with laid-out research foundations, and specialized upgrades. As rethinking is at this point not just about reducing expenses, a developing requirement for viability, quality, and development is expected to help industry extension.
The Asia Pacific drug discovery services market is anticipated to develop the highest growth owing to the accessibility of qualified individuals, less expensive costs, a successful administrative climate, and great information, the Region is rapidly turning into a center for re-appropriating drug improvement exercises. The second-biggest drug market on the planet, Japan, is expected to furnish CROs with a sizable potential, driving the business.
The fast improvement of innovation and the development of metropolitan regions impel the European drug discovery services market. The improvement of biologics and biosimilars has seen an expansion in speculation from biopharmaceutical firms, which is liable for the ascent in the number of approved drugs in Europe. The European drug discovery services market is expected to be driven by expanding consumptions made by many significant organizations in different clinical and non-clinical examination exercises that are moved to a few CRO specialist co-ops and help with proficient item improvement.

Major Players

Abbott Laboratories Inc., Advinus Therapeutics, Albany Molecular Research Inc. (AMRI), Aurigene, Agilent Technologies Ubiquigent, AstraZeneca PLC, Retrogenix (U.K.), Charles River Laboratories International, Eurofins, and Liverpool ChiroChem Ltd.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING RESEARCH & DEVELOPMENT EXPENDITURE

4.2.2 RISING DRUG DEVELOPMENT OUTSOURCING

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY POLICIES AND COSTS ASSOCIATED TO DRUG DISCOVERY

4.4 OPPORTUNITY

4.4.1 TECHNOLOGICAL ADVANCEMENTS IN DRUG DISCOVERY

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)

5.1.2 SERVICE CUSTOMIZATION

5.1.2.1 R&D

5.1.2.2 GOOD LABORATORY PRACTICES (GLP)

5.1.3 CUSTOMER PURCHASE SUPPORT

5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 COVID-19 IMPACT ON THE DRUG DISCOVERY SERVICES MARKET

5.3.1 IMPACT ON R&D

5.3.2 IMPACT ON PRICING

5.3.3 IMPACT ON MARKET GROWTH

6 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

6.1 OVERVIEW

6.2 SMALL MOLECULE DRUG

6.3 BIOLOGICS DRUG

7 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TYPES OF SERVICES

7.1 OVERVIEW

7.2 DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES

7.3 PHARMACEUTICAL SERVICES

7.4 MEDICINAL CHEMISTRY

7.5 BIOLOGICAL SERVICES

7.6 MEDICATION

8 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

8.1 OVERVIEW

8.2 ONCOLOGY

8.3 CARDIOVASCULAR DISEASES

8.4 RESPIRATORY DISEASES

8.5 DIABETES

8.6 OTHERS

9 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TECHNOLOGY

9.1 OVERVIEW

9.2 HIGH THROUGHPUT SCREENING

9.3 BIOCHIPS

9.4 PHARMACOGENOMICS AND PHARMACOGENETICS

9.5 METABOLOMICS

9.6 OTHERS

10 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3 RESEARCH & ACADEMIC INSTITUTES

10.4 OTHERS

11 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 US

11.2.2 CANADA

11.3 EUROPE

11.3.1 GERMANY

11.3.2 FRANCE

11.3.3 UK

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 AUSTRALIA

11.4.5 SOUTH KOREA

11.4.6 REST OF ASIA-PACIFIC

11.5 REST OF THE WORLD

11.5.1 MIDDLE EAST

11.5.2 AFRICA

11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 COMPETITIVE BENCHMARKING

12.3 MAJOR GROWTH STRATEGY IN DRUG DISCOVERY SERVICES MARKET

12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN DRUG DISCOVERY SERVICES MARKET

12.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.5.1 SERVICE LAUNCH

12.5.2 MERGERS & ACQUISITIONS

12.5.3 PARTNERSHIP/COLLABORATION

12.6 MAJOR PLAYERS SALES ANALYSIS

12.6.1 SALES & OPERATING INCOME, 2021 (USD MILLION)

12.6.2 MAJOR PLAYERS R&D ANALYSIS, 2021 (USD MILLION)

13 COMPANY PROFILE

13.1 THERMO FISHER SCIENTIFIC INC.

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 SERVICES OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 ARAGEN LIFE SCIENCES PVT. LTD.

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 SERVICES OFFERED

13.2.4 KEY DEVELOPMENTS

13.2.5 KEY STRATEGIES

13.3 PIRAMAL PHARMA SOLUTIONS

13.3.1 COMPANY OVERVIEW

13.3.2 FINANCIAL OVERVIEW

13.3.3 SERVICES OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 KEY STRATEGIES

13.4 CURIA GLOBAL, INC.

13.4.1 COMPANY OVERVIEW

13.4.2 FINANCIAL OVERVIEW

13.4.3 SERVICES OFFERED

13.4.4 KEY STRATEGIES

13.5 CHARLES RIVER LABORATORIES

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 SERVICES OFFERED

13.5.4 KEY DEVELOPMENTS

13.5.5 SWOT ANALYSIS

13.5.6 KEY STRATEGIES

13.6 EUROFINS SCIENTIFIC

13.6.1 COMPANY OVERVIEW

13.6.2 FINANCIAL OVERVIEW

13.6.3 SERVICES OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 SWOT ANALYSIS

13.6.6 KEY STRATEGIES

13.7 IQVIA

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 SERVICES OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 SWOT ANALYSIS

13.7.6 KEY STRATEGIES

13.8 EVOTEC

13.8.1 COMPANY OVERVIEWS

13.8.2 FINANCIAL OVERVIEW

13.8.3 SERVICES OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 KEY STRATEGIES

13.9 WUXI APPTEC CO., LTD.

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 SERVICES OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 SWOT ANALYSIS

13.9.6 KEY STRATEGIES

13.10 LABORATORY CORPORATION OF AMERICA HOLDINGS

13.10.1 COMPANY OVERVIEW

13.10.1 FINANCIAL OVERVIEW

13.10.2 SERVICES OFFERED

13.10.3 KEY DEVELOPMENTS

13.10.4 KEY STRATEGIES

13.11 SELVITA

13.11.1 COMPANY OVERVIEW

13.11.2 FINANCIAL OVERVIEW

13.11.3 SERVICES OFFERED

13.11.4 KEY DEVELOPMENTS

13.11.5 SWOT ANALYSIS

13.11.6 KEY STRATEGIES

13.12 SYGNATURE DISCOVERY

13.12.1 COMPANY OVERVIEW

13.12.2 FINANCIAL OVERVIEW

13.12.3 SERVICES OFFERED

13.12.4 KEY DEVELOPMENTS

13.12.5 SWOT ANALYSIS

13.12.6 KEY STRATEGIES

13.13 SYMERES

13.13.1 COMPANY OVERVIEW

13.13.2 FINANCIAL OVERVIEW

13.13.3 SERVICES OFFERED

13.13.4 KEY DEVELOPMENTS

13.13.5 SWOT ANALYSIS

13.13.6 KEY STRATEGIES

13.14 NUCHEM SCIENCES INC.

13.14.1 COMPANY OVERVIEW

13.14.2 FINANCIAL OVERVIEW

13.14.3 SERVICES OFFERED

13.14.4 KEY STRATEGIES

13.15 PARAZA PHARMA, INC.

13.15.1 COMPANY OVERVIEW

13.15.2 FINANCIAL OVERVIEW

13.15.3 SERVICES OFFERED

13.15.4 KEY DEVELOPMENTS

13.15.5 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES

14.2 RELATED REPORTS

The post Drug Discovery Services Market research report Forecast to 2030 first appeared on CRI Report.